If we are serious about narrowing health gaps, then our environmental protections must be safeguarded against political ...

We must resist the temptation to reinterpret the Bayh-Dole Act even in an effort to improve the affordability of and access ...

Valerie Lehman is an Assistant Research Director on the Health Care Transformation team at the Duke-Margolis Institute for Health Policy and manages the rapid lear ...

Health Affairs' Rob Lott interviews Michael T. Osterholm, the director of the Center for Infectious Disease Research and ...

Prior authorization is a barrier to accessing medications for opioid use disorder (MOUD). Although private insurance covered about one-third of patients with OUD in 2023, the understanding of prior ...

Under the Consolidated Appropriations Act, 2023, which required the provision of national twelve-month continuous Medicaid eligibility for children up to age nineteen, children’s Medicaid enrollment ...

In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...

Without policy intervention to address average sales price-based challenges to biosimilar market sustainability, there is a ...

US v. Skrmetti undermined constitutional guardrails that guarantee rigorous assessment of medical justifications for policies limiting the rights of transgender people and women, creating a need and ...

Ryan N. Hansen, PharmD, PhD, is professor and chair of the Department of Pharmacy, and faculty in the CHOICE Institute, School of Pharmacy, University of Washington, and chief technology officer at ...

The No Surprises Act has protected patients from surprise medical bills. However, the law’s incentives for insurers acting as ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...